Prospekta

DRUG3 trials

Sponsors

Materia Medica Holding

Conditions

Attention Deficit Hyperactivity DisorderPost-acute COVID-19 SyndromeVascular Dementia

Phase 3

Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.

CompletedNCT04552041

Materia Medica HoldingVascular Dementia

Start: 2020-12-03End: 2022-09-22Updated: 2024-10-28

Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children

CompletedNCT04569357

Materia Medica HoldingAttention Deficit Hyperactivity Disorder

Start: 2020-11-20End: 2022-02-18Updated: 2024-08-01

Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.

CompletedNCT05074888

Materia Medica HoldingPost-acute COVID-19 Syndrome

Start: 2021-10-15End: 2022-06-08Updated: 2024-09-23